Galectin Therapeutics

GALT · NASDAQ

$3.43−$0.065 (−1.86%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.50

GALT analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $11.22 (+227.1% upside)

Low: $11.11
Now: $3.43
High: $11.55

Upgrades and downgrades

The latest rating actions, newest first

GALT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Jun 23, 2026	Maintains	Buy	$11.00	17%
HC Wainwright & Co.	Dec 17, 2025	Maintains	Buy	$6.00 → $11.00	17%

The case for and against

Updated May 8, 2025

Bull case

Galectin Therapeutics Inc. is positioned favorably due to the potential for a more rapid development path and favorable FDA alignment, which could accelerate the commercialization of belapectin as a treatment for liver fibrosis. The upcoming Phase 2b 18-month data readout is expected to serve as a crucial milestone, with indications that the revised trial design may enhance the likelihood of success by utilizing a larger and better-powered sample size. Furthermore, the positive response from investigators, as evidenced by the oversubscription of the NAVIGATE trial, suggests strong confidence in belapectin's clinical potential and may act as a significant catalyst for the stock.

Bear case

Galectin Therapeutics Inc. reported a substantial net loss of $11.2 million in the third quarter of 2024, raising concerns about its financial health and sustainability in the face of ongoing clinical trials. The company's primary drug candidate, belapectin, demonstrated disappointing results in the NAVIGATE trial, failing to meet management's expected benefits and casting doubt on its future development for treating liver fibrosis. Additionally, uncertainties surrounding clinical trial outcomes, potential safety issues, and funding challenges for future phases of development contribute to a negative outlook on the company's stock performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.